“Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure”, J of Skin, vol. 9, no. 6, p. s616, Nov. 2025, doi: 10.25251/n1p8w126.